Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Share tips 2026: this week’s top stock picks
Share tips 2026: MoneyWeek’s roundup of the top stock picks this week – here’s what the experts think you should buy.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
1. Emerson Electric (NYSE: EMR) Kiplinger’s Personal Finance Industrial-technology and automation specialist Emerson has spent the past few years selling off some businesses and acquiring others in order to focus on automation. The strategy is paying off: management has raised 2026 forecasts. Sri Iyer, managing director at investment firm Guardian Capital, believes Emerson benefits from AI given the trend towards automating and digitalising factories and warehouses to make equipment more efficient. The company has raised its dividend for 69 consecutive years, but the payouts only make up a third of its free cash flow, so Iyer believes that Emerson can keep increasing dividends by an annual 3%-4% over the next few years. $163
2. Tecan (SWX: TECN) Investors’ Chronicle AI has produced so many new potential drug combinations for testing that laboratories have become a major bottleneck. Enter Switzerland’s medical technology group Tecan, which makes automated testing machines for laboratories. These are essentially robots that handle the laboratory work that humans do far more slowly; they also feed back data to the pharma group’s AI agents. The group recently partnered with chip giant Nvidia to add AI to the software that collects information from its instruments. Sales rose 3.4% in the first half of 2026, and guidance implies a strong second half. A new management team has cut less profitable areas of the business. Despite growing competition from the likes of pharma giant Roche, Tecan has found a “powerful niche”. CHF243
3. BB Biotech (SWX: BION) WirtschaftsWoche This Swiss investment company focuses purely on biotechnology outfits worldwide, making it a one-stop shop for the sector. Holdings range from market leaders Amgen and Gilead Sciences (specialists in cardiovascular drugs and infectious diseases, respectively) to more obscure companies in promising subsectors such as oncology and autoimmune diseases. The shares are on a discount of around 12% to their net asset value (NAV) and offer a dividend yield of 4.4%. CHF50
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Explore More
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
